Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States: A Cohort Study by Kerlikowske, Karla
Comparative Effectiveness of Digital Versus Film-Screen
Mammography in Community Practice in the United States:
A Cohort Study
Karla Kerlikowske, MD, Rebecca A. Hubbard, PhD, Diana L. Miglioretti, PhD, Berta M.
Geller, EdD, Bonnie C. Yankaskas, PhD, Constance D. Lehman, MD, PhD, Stephen H.
Taplin, MD, MPH, and Edward A. Sickles, MD for the Breast Cancer Surveillance
Consortium
University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San
Francisco, California; Group Health Research Institute, Group Health Cooperative, University of
Washington School of Public Health and Community Medicine, and University of Washington
School of Medicine, Seattle, Washington; Health Promotion Research, University of Vermont,
College of Medicine, Burlington, Vermont; University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina; and Applied Research Program, National Cancer Institute, Rockville, Maryland.
Abstract
Background—Few studies have examined the comparative effectiveness of digital versus film-
screen mammography in U.S. community practice.
Objective—To determine whether the interpretive performance of digital and film-screen
mammography differs.
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Setting—Mammography facilities in the Breast Cancer Surveillance Consortium.
Participants—329 261 women aged 40 to 79 years underwent 869 286 mammograms (231 034
digital; 638 252 film-screen).
Measurements—Invasive cancer or ductal carcinoma in situ diagnosed within 12 months of a
digital or film-screen examination and calculation of mammography sensitivity, specificity, cancer
detection rates, and tumor outcomes.
Results—Overall, cancer detection rates and tumor characteristics were similar for digital and
film-screen mammography, but the sensitivity and specificity of each modality varied by age,
tumor characteristics, breast density, and menopausal status. Compared with film-screen
mammography, the sensitivity of digital mammography was significantly higher for women aged
60 to 69 years (89.9% vs. 83.0%; P = 0.014) and those with estrogen receptor-negative cancer
(78.5% vs. 65.8%; P = 0.016); borderline significantly higher for women aged 40 to 49 years
(82.4% vs. 75.6%; P = 0.071), those with extremely dense breasts (83.6% vs. 68.1%; P= 0.051),
and pre- or perimenopausal women (87.1% vs. 81.7%; P = 0.057); and borderline significantly
lower for women aged 50 to 59 years (80.5% vs. 85.1%; P = 0.097). The specificity of digital and
film-screen mammography was similar by decade of age, except for women aged 40 to 49 years
(88.0% vs. 89.7%; P< 0.001).
Limitation—Statistical power for subgroup analyses was limited.
Conclusion—Overall, cancer detection with digital or film-screen mammography is similar in
U.S. women aged 50 to 79 years undergoing screening mammography. Women aged 40 to 49
years are more likely to have extremely dense breasts and estrogen receptor-negative tumors; if
they are offered mammography screening, they may choose to undergo digital mammography to
optimize cancer detection.
Primary Funding Source—National Cancer Institute.
Of the 12 445 accredited mammography machines in the United States as of 1 October
2010, 8748 (70.3%) are full-field digital (1). Despite the rapid dispersion of full-field digital
mammography, few studies on the accuracy of digital mammography in the United States
have been published (2–4), and no studies have compared this technology with film-screen
mammography in U.S. community practice.
Studies comparing digital with film-screen mammography in Europe and the United States
have produced conflicting findings (5). DMIST (Digital Mammography Imaging Screening
Trial) performed film-screen and digital mammography in asymptomatic U.S. women at the
same screening encounter. It found that overall accuracy of film-screen and digital
mammography for breast cancer detection was similar (2) but that digital mammography
was more accurate in pre- or perimenopausal women younger than 50 years with
mammographically dense breasts and less accurate in women aged 65 years or older with
non-dense breasts (3). The Oslo II study randomly assigned women aged 45 to 69 years to
undergo digital or film-screen mammography and reported higher cancer detection rates and
lower specificity with digital than with film-screen mammography (6). In a population-
based screening program in Spain, recall rate was higher among women undergoing digital
mammography than film-screen mammography, and cancer detection rates were similar (7).
The United Kingdom’s breast cancer screening program for women aged 50 years or older
found no difference in cancer detection or recall rates (8). In a population-based screening
program in the Netherlands, recall rate and detection rates for ductal carcinoma in situ
(DCIS) were higher among women undergoing digital mammography than those having
film-screen mammography, but detection rates for invasive cancer were similar (9).
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The inconsistent results across studies may be due to small numbers of digital examinations
and, thus, few cases of breast cancer associated with these examinations (n = 25 to 254). In
addition, the studies did not account for correlation among mammography examinations
performed at the same facility by the same radiologist or for secular trends in mammography
performance. Study design also varies considerably, ranging from randomized, controlled
trials to paired examinations, retrospective cohorts, and population-based cohorts. Other
factors that may contribute to the divergent results include single- versus double-reading,
readers’ experience, and practice environment (5).
We sought to compare the accuracy of digital mammography with that of film-screen
mammography and tumor outcomes according to age, breast density, menopause status, and
tumor subtype at diagnosis among women aged 40 to 79 years undergoing screening
mammography in the Breast Cancer Surveillance Consortium (BCSC). The BCSC (http://
breastscreening.cancer.gov) is a large population-based cohort of community-based imaging
facilities in the United States.
Methods
Data Source
Data were pooled from 4 mammography registries that participate in the BCSC (10) and
collect data from at least 1 facility that performs digital mammography: San Francisco
Mammography Registry, Vermont Breast Cancer Surveillance System, New Hampshire
Mammography Network, and Carolina Mammography Registry. These registries collect
information on breast imaging examinations performed in their defined catchment areas.
Each breast-imaging registry annually links women in its registry to a state tumor registry or
regional Surveillance, Epidemiology and End Results program that collects population-
based cancer data. Three of the 4 registries also link with pathology databases. Each registry
obtains annual approval from its institutional review board for consenting processes or a
waiver of consent, enrollment of participants, and ongoing data linkages for research
purposes. The BCSC Statistical Coordinating Center and each registry adhere to strict
confidentiality procedures; comply with the Health Insurance Portability and Accountability
Act; and have a Federal Certificate of Confidentiality and other protections of research
subjects, radiologists, and mammography facilities.
Participants
The study sample included bilateral digital and film-screen mammography examinations
performed between 1 January 2000 and 31 December 2006 among women aged 40 to 79
years who did not have a history of breast cancer or breast implants. Mammography
examinations that occurred after 31 December 2006 were not included to ensure at least 12
months for reporting cases of cancer to tumor registries. Cancer ascertainment from cancer
registries is estimated to be more than 94.3% complete (11).
Measurements and Definitions
Demographic characteristics and breast health history were obtained by using a self-
administered questionnaire (available at http://breastscreening.cancer.gov) that was
completed at each screening examination. Women were considered to have a family history
of breast cancer if they reported having at least 1 first-degree relative (mother, sister, or
daughter) with breast cancer. Postmenopausal women were defined as those who had had
both ovaries removed, those who reported that their periods had stopped naturally, those
currently using hormone therapy, and those aged 55 years or older. Women were considered
to be premenopausal if their menstrual periods had not stopped and perimenopausal if they
were not sure whether their periods had stopped. Women were considered to have missing
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menopausal status if they had had a hysterectomy without bilateral oophorectomy and were
not using hormone therapy or if their menopause status could not be determined from
available information.
We used self-reported race and ethnicity to categorize women as non-Hispanic white, non-
Hispanic black, Hispanic, Asian/Native Hawaiian/Pacific Islander, Native American/Native
Alaskan, or other/mixed race.
Time between mammography examinations was determined by using the dates of prior
mammography examinations recorded in each mammography registry (87%); if these were
not available, we used self-reported information (13%) collected at the screening
examination. A mammography examination was determined to be the first if a woman
reported no previous examination and no prior mammogram was found in a registry.
Mammographic breast density was assigned in clinical practice by a radiologist at the time
of mammography interpretation. The Breast Imaging Reporting and Data System (BI-
RADS) density categories used were almost entirely fat, scattered fibroglandular densities,
heterogeneously dense, and extremely dense (12).
Our primary measure was the initial screening mammography assessment, which we
categorized as positive or negative by using standard BI-RADS and BCSC definitions (12,
13) that indicate whether a woman was recalled to undergo additional evaluation on the
basis of screening views only (12, 13), and the association of initial assessment with cancer
outcomes. Standard BCSC definitions of true-positive, false-positive, true-negative, and
false-negative results were used to calculate breast cancer and recall rates and the sensitivity,
specificity, and positive predictive value of mammography (13).
A mammography examination was associated with breast cancer if invasive carcinoma or
DCIS was diagnosed within 12 months of and before the next screening examination.
Women with lobular carcinoma in situ only were not considered to have cancer. Stage at
diagnosis was classified according to the tumor, lymph node, metastasis system based on the
criteria of the American Joint Committee on Cancer, 6th edition, as stage 0, I, IIA, IIB, III,
or IV (14). Invasive cancers were classified according to their estrogen receptor status,
lymph node status, tumor size, and grade.
Statistical Analysis
All analyses were performed by using the screening examination as the unit of analysis;
women may have had more than 1 mammography examination during the study period.
Frequency distributions of risk factors for breast cancer and BI-RADS density scores and
assessments were determined for digital and film-screen examinations.
We modeled mammography performance measures by using binomial generalized linear
mixed models with a logit link, including normally distributed facility random effects to
account for correlation among mammography examinations performed at the same facility.
To account for differences between facilities performing digital mammography and those
performing only film-screen mammography, we included a binary indicator of whether a
facility performed any digital examinations during the study period. All models were
adjusted for factors related to performance and timing of digital examinations: age,
examination year, time between screenings (within 1, 2, or ≥3 years, or first screening
examination), and BCSC registry. Adjusted performance measures were estimated from
these models by using indirect standardization to ensure identical distributions of covariates
among digital and film-screen examinations (15, 16), as described elsewhere (17, 18).
Performance estimates were calculated for a facility at the median of the distribution of
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facility random effects. Standard errors for adjusted performance measures were calculated
by using the delta method.
Separate performance measures were calculated and reported for digital and film-screen
mammography from facilities that either switched to digital (66% of facilities) during the
study period or performed both film and digital mammography. Film-screen examinations (n
= 994 000) from facilities that did not perform digital mammography during the study
period were also included in all analyses to adjust for possible secular trends in
mammography performance.
Two-sided statistical tests resulting in P values less than 0.050 were considered statistically
significant, and values between 0.050 and 0.100 were considered borderline significant.
Sensitivity analyses were done to evaluate the effect of correlation among mammography
examinations interpreted by the same radiologist by including a random effect for
radiologist in addition to facility (Appendix, available at www.annals.org). Allowing for
within-radiologist correlation among mammography examinations had no qualitative effect
on regression model results; this factor was therefore not included in the main model, as it
reduced our sample size (because a radiologist identifier was missing for some
examinations).
We also conducted a sensitivity analysis of the effect of adjustment for the proportion of
digital examinations performed at a facility (Appendix). In this analysis, we decomposed the
effect of type of mammography into between-and within-facility components by using the
methods of Neuhaus and Kalbfleisch (19); this had no qualitative effect on results and was
therefore not included in the main model. The Appendix shows performance estimates for
facilities at the 25th and 75th percentiles of the random effects distribution to quantify
variability across facilities.
To assess whether examinations performed in the first year (n= 60 383 [26.1%]) after a
facility implemented digital mammography affected performance estimates, we excluded
these examinations in additional sensitivity analyses.
Role of the Funding Source
This study was funded by the National Cancer Institute. A senior scientist from the National
Cancer Institute participated in the study design and preparation of the manuscript. The
views expressed in this article do not represent those of the National Cancer Institute, and
this organization had no role in the final decision to submit the manuscript for publication.
Results
Among 329 260 women aged 40 to 79 years, 869 286 screening mammography
examinations were performed (231 034 digital and 638 252 film-screen) and breast cancer
was diagnosed in 4046 women (1054 digital and 2992 film-screen examinations), primarily
at nonacademic facilities (83%). Women undergoing digital compared with film-screen
mammography were similar in age, race or ethnicity, and time since last mammography
examination, and they were equally likely to have a first-degree relative with breast cancer
and dense breasts (Table 1). Women undergoing digital mammography were slightly more
likely to have an initial BI-RADS assessment that indicated a need for additional imaging
evaluation. The median time that facilities had performed digital mammography was 2.3
years.
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Performance Measures for Digital Versus Film-Screen Mammography
Overall—For the most part, digital and film-screen mammography were similar in rates of
breast cancer per 1000 examinations (overall, invasive cancer, and DCIS), cancer detection,
false-negative results, breast biopsies, and sensitivity. Recall rate and specificity differed
significantly, but the differences were small (Table 2). Excluding digital examinations from
the first year during which a facility performed digital mammography did not change the
significance of any of our comparisons of the performance of digital and film-screen
mammography (data not shown).
By Age, BI-RADS Breast Density, and Menopausal Status—Rates of cancer
detection per 1000 examinations by decade of age were similar for digital and film-screen
mammography (Table 3). Sensitivity to detect invasive cancer or DCIS was borderline
significantly higher for digital than for film-screen mammography among women aged 40 to
49 years (82.4% vs. 75.6%; P = 0.071), significantly higher among women aged 60 to 69
years (89.9% vs. 83.0%; P = 0.014), and borderline significantly lower for women aged 50
to 59 years (80.5% vs. 85.1%; P = 0.097). Specificity was similar for digital and film-screen
mammography for all decades of age, except women aged 40 to 49 years (88.0% vs. 89.7%;
P< 0.001).
Rates of cancer detection per 1000 examinations across breast density categories were
similar for digital and film-screen mammography (Table 3). Sensitivity was similar for
digital and film-screen mammography for all density categories except extremely dense
breasts, for which sensitivity was borderline significantly higher for digital than for film-
screen mammography (83.6% vs. 68.1%; P = 0.051). Specificity was significantly lower for
digital than for film-screen mammography (range, 0.6% to 1%) for all breast density
categories (P ≤ 0.010). Sensitivity was borderline significantly higher for digital than for
film-screen mammography in pre- or perimenopausal women (87.1% vs. 81.7%; P = 0.057)
and specificity was lower (88.7% vs. 90.2%, P< 0.001) (Table 3).
We examined the subgroups in which DMIST (3) reported that the sensitivity of digital
mammography differed from that of film-screen mammography. In pre- or perimenopausal
women aged 40 to 49 years with extremely dense breasts, among whom there were 66 cases
of breast cancer, a nonsignificant trend was seen toward higher sensitivity for digital than for
film-screen mammography (86.8% vs. 62.3%; odds ratio, 4.1 [95% CI, 0.7 to 23.3]; P =
0.111). For women aged 65 to 79 years with fatty breasts, among whom there were 48 cases
of breast cancer, the sensitivity of digital versus film-screening mammography was similar
(83.7% vs. 89.1%; odds ratio, 0.6 [CI, 0.1 to 7.3]; P = 0.69).
By Estrogen Receptor Status—Sensitivity was significantly higher for digital than for
film-screen mammography among women aged 40 to 79 years who had estrogen receptor–
negative cancer (78.5% vs. 65.8%; P = 0.016), was higher for all decades of age, and was
significantly higher for women aged 40 to 49 years (95.2% vs. 54.9%; P = 0.007) (Table 4).
Sensitivity was similar for women aged 40 to 79 years who had estrogen receptor–positive
cancer (83.5% vs. 82.7%; P = 0.66) and for all decades of age except 60 to 69 years, for
which sensitivity was higher for digital than for film-screen mammography (90.6% vs.
82.3%; P = 0.017) (Table 4).
Tumor Characteristics, by Type of Mammography
The distribution of types of breast cancer by tumor characteristics did not vary for digital
and film-screen mammography (Table 5). The proportion of early stage (I and IIA) versus
advanced (IIB, III, IV) disease also did not vary by type of mammography (P = 0.168).
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Digital mammography has diffused rapidly in countries in which screening mammography
is available, despite limited data on the comparative effectiveness relative to film-screen
mammography. We compared digital and film-screen mammography in a large number of
U.S. community mammography facilities during a period when cancer detection using film-
screen mammography has improved (20) and digital mammography technology has
advanced. Overall, we found digital and film-screen mammography to be similar in cancer
detection rates and the proportion of cancer cases diagnosed at an early stage. Specificity
was similar for all decades of age except women 40 to 49 years, for whom specificity was
lower for digital than film-screen mammography. In addition, we found that women with
extremely dense breasts benefit from the higher sensitivity of digital than film-screen
mammography, and we provide new evidence that digital mammography is better at
detecting estrogen receptor–negative breast cancer, particularly in women aged 40 to 49
years.
Breast cancer may not be detected on mammography if a radiologist does not identify a
visible lesion or a tumor is obscured by normal breast tissue. In addition, an imperceptible
tumor may grow quickly and be discovered clinically before the next screening examination.
High mammographic breast density is associated with decreased cancer detection on
mammography (18, 21), in part because cancerous and normal fibroglandular tissue have
similar radiographic attenuation. Breast tumors that are not detected by film-screen
mammography tend to be estrogen receptor–negative, high-grade, and large and have high
mitotic activity in women with dense tissue patterns (22, 23).
Digital mammography was developed in part to improve the detection of breast cancer in
dense breasts by improving the ability to distinguish normal dense breast tissue from
isodense invasive cancer. We would therefore expect digital mammography to improve
cancer detection in women who have dense breast tissue and those who present with fast-
growing invasive cancer in which the tumor is difficult to discern from normal dense tissue.
Our results support this supposition: We found that digital mammography had higher
sensitivity than film-screen mammography in women with dense breasts and women with
estrogen receptor–negative tumors. Thus, women aged 40 to 49 years may benefit most from
digital mammography because the proportion of women in this group with extremely dense
breasts (about 12% to 15%) (24) and estrogen receptor–negative tumors (25) is higher than
that of women aged 50 years or older; however, they may experience additional harms. If 10
000 women aged 40 to 49 years are screened with digital mammography, 2 additional cases
of cancer will be identified for every 170 additional false-positive examinations.
DMIST identified subgroups of women in whom digital mammography may perform better
than film-screen mammography (for example, those younger than 50 years, those with
radiographically dense breasts, and pre- or peri-menopausal women) (2). The main
conclusions of DMIST are based on the area under the receiver-operating characteristic
curve, constructed from a 7-point mammography assessment scale. These curves estimated
the sensitivity and specificity associated with classifying mammography examinations as
normal or abnormal at each level of the assessment scale. This comparison of the
performance of digital and film-screen mammography, which is based on an interpretive
approach not used in clinical practice, magnifies the difference between modalities and tends
to have greater statistical significance that stems from comparing sensitivity and specificity
across all possible cut points rather than for an overall mammography result of normal or
abnormal. When the DMIST investigators compared the overall sensitivity and specificity of
digital versus film-screen mammography by using the 7-point scale, they did not find a
difference in sensitivity for women of all ages combined, pre- or perimenopausal women, or
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those with dense breasts and borderline higher sensitivity and slightly lower specificity for
women younger than 50 years (2), similar to the results we report for women aged 40 to 49
years. Although our estimates of the sensitivity of digital compared with film-screen
mammography tend to be higher for pre- or perimenopausal women aged 40 to 49 years
with extremely dense breasts and lower for women aged 65 to 79 years with almost entirely
fat breast density, similar to data reported in DMIST (2), the differences were not
statistically significant, possibly because of the small number of cases of breast cancer in
these subgroups and the somewhat different age and breast density groups than those in
DMIST.
We classified mammography examinations as normal or abnormal on the basis of initial BI-
RADS assessments as collected in clinical practice because the study goal was to evaluate
the influence of screening modality. The BI-RADS assessment does not provide a reliable
basis for estimating receiver-operating characteristic curves in screening mammography
because the BI-RADS scale is not ordinal, but rather a dichotomy of normal or abnormal
assessment (26). Our results on the performance of digital and film-screen mammography in
community practice are clinically relevant because we report overall sensitivity and
specificity based on the main decision by radiologists during interpretation of screening
mammography of whether to recall a woman for further diagnostic evaluation. Diagnostic
evaluations are typically performed on a different day, which creates anxiety during the
waiting period for some women. Diagnostic evaluations also contribute to health care costs
and additional radiation exposure and discomfort. False-positive recalls based on the initial
BI-RADS assessment are the most common “harm” of mammography and are thus an
important and clinically relevant outcome to measure.
Our study included a large, diverse population-based sample and large number of outcomes.
We took into account secular trends in mammography performance and adjusted for facility-
level differences by including a facility-specific random effect. Although more than 1000
cases of breast cancer were identified among women undergoing digital mammography, we
did not have the statistical power to examine subgroups of women with multiple risk factors
that may influence breast cancer detection. Misclassification of BI-RADS density because of
modest interrater agreement between radiologists (27, 28) could result in under- or
overestimation of performance measures by density category. We evaluated numerous
comparisons; some may be significant by chance alone.
We found small differences in the proportion of women with abnormal results by screening
modality and did not find differences in tumor characteristics or rate of detection of invasive
cancer or DCIS. Of note, we found that the sensitivity of digital and film-screen
mammography to detect breast cancer is similar and relatively high among women aged 50
to 79 years. Women who have access to only digital or only film-screen mammography
should be encouraged by our results, because both modalities seem to be equally effective in
detecting breast cancer, in particular among women aged 50 to 79 years.
An important factor that we did not address in our study is the quality of mammography
interpretation. Whether mammography examinations are interpreted at large-volume
facilities (29) or by radiologists who are experienced in mammography interpretation (30)
may influence the accuracy of mammography at least as much as whether the screening
modality is digital or film-screen.
In summary, overall, cancer detection with digital and film-screen mammography is similar
in U.S. women aged 50 to 79 years undergoing screening mammography. Women aged 40
to 49 years who are being offered screening mammography may choose to undergo digital
mammography to optimize cancer detection, because digital mammography is better at
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detecting tumors in extremely dense breasts and estrogen receptor–negative tumors, both of
which are more likely in this age group.
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Results of Regression Models Including Random Effects for Facility and
Radiologist
In our primary analyses, we adjusted for clustering at the facility level. However, the same
radiologist can interpret multiple mammography examinations leading to clustering among
radiologists. Because radiologists are largely nested within facilities, adjustment for facility
accounts for much of the correlation between observations that arises from radiologist-level
clustering. To explore the sensitivity of our results to within-radiologist clustering, we
repeated the analyses reported in Tables 2 to 4, but allowed for both facility and radiologist
random effects. Results of these analyses are shown in Appendix Tables 1 to 3
Results Decomposing Digital Effect Into Within- and Between-Components
Rather Than Using Binary Indicators of Film-Only Versus Digital
Mammography
In our primary analysis, we assumed that between-facility differences can be entirely
captured by a binary indicator representing whether a facility performed any digital
mammography. We performed a sensitivity analysis to model the between-facility effect by
adjusting for the proportion of digital mammography performed, rather than using a
dichotomous classification of any digital mammography versus none. This analysis follows
the approach of Neuhaus and Kalbfleisch (19). We repeated the analyses reported in Tables
2 to 4 by using separate between- and within-facility components for digital mammography
effect.
Results of these analyses are shown in Appendix Tables 4 to 6. In these results we compare
the performance of digital mammography with that of film-screen mammography (within-
facility effect) while holding the proportion of digital mammograms performed by the
facility (between-facility effect) constant. Odds ratios and P values for digital versus film-
screen mammography represent the within-facility effect of digital mammography.
Performance Measures of Screening Mammography for Facilities at the
25th and 75th Percentiles of the Distributions of Facility Performance
The performance estimates reported in Tables 2 to 4 are for a facility with median
performance. To demonstrate the extent of between-facility variability in performance, we
report performance estimates for facilities at the 25th and 75th percentiles of the distribution
of facility performance for each measure (Appendix Tables 7 to 9). We also report the SDs
for the facility random effects in our logistic-normal random intercept model.
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Digital mammography is widely adopted despite limited evidence comparing its accuracy
with that of film-screen methods.
Contribution
In a large sample of women screened in community settings, digital and film-screen
mammography yielded similar cancers detection rates and proportions of early-stage
cancer diagnosed. Digital screening had higher sensitivity in women with dense breasts
and was better at detecting estrogen receptor–negative cancer, but specificity was lower
for women aged 40 to 49 years than for other decades.
Caution
Some subgroups were small, and the study did not examine breast cancer mortality rates.
Implication
Screening methods are similarly effective, but sensitivity and specificity tradeoffs occur
in some subgroups.
—The Editors
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Table 1





Total examinations 231 034 638 252
Cancer cases within 1 y of mammography 1054 (0.5) 2992 (0.5)
Age
    40–49 y 77 392 (33.5) 221 696 (34.7)
    50–59 y 78 514 (34.0) 216 073 (33.9)
    60–69 y 47 277 (20.5) 123 870 (19.4)
    70–79 y 27 851 (12.1) 76 613 (12.0)
Previous mammography
    First 10 215 (4.4) 22 071 (3.5)
    Subsequent 219 550 (95.6) 611 900 (96.5)
Family history of breast cancer 30 470 (15.3) 79 427 (14.2)
Postmenopausal 141 995 (69.3) 391 752 (68.1)
BI-RADS breast density
    Almost entirely fat 14 203 (8.8) 26 475 (7.4)
    Scattered fibroglandular densities 63 377 (39.4) 158 994 (44.7)
    Heterogeneously dense 73 004 (45.4) 143 353 (40.3)
    Extremely dense 10 184 (6.3) 27 240 (7.7)
BI-RADS assessment
    Negative 147 818 (64.0) 320 400 (50.2)
    Benign finding 56 383 (24.4) 254 389 (39.9)
    Probably benign 933 (0.4) 5392 (0.8)
    Need additional imaging evaluation 25 503 (11) 56 820 (8.9)
    Suspicious 366 (0.2) 1099 (0.2)
    Malignant 31 (0.0) 152 (0.0)
Time since previous mammography
    No previous mammography 10 215 (4.6) 22 071 (3.8)
    9–18 mo 149 580 (67.4) 387 038 (65.8)
    19–30 mo 37 416 (16.9) 110 162 (18.7)
    >30 mo 24 655 (11.1) 68 770 (11.7)
Race
    White, non-Hispanic 157 353 (69.3) 442 960 (73.4)
    Black, non-Hispanic 6847 (3.0) 28 213 (4.7)
    Asian/Native Hawaiian/Pacific Islander 47 560 (20.9) 93 538 (15.5)
    American Indian/Alaskan Native 544 (0.2) 1372 (0.2)
    Hispanic 10 615 (4.7) 26 424 (4.4)
    Other 4134 (1.8) 11 115 (1.8)
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BI-RADS = Breast Imaging Reporting and Data System.
*
Missing values include 1.5% for previous mammography, 14.1% for family history, 12.2% for menopausal status, 24.6% for BI-RADS breast
density, 8.1% for time since previous mammography, and 5.3% for race or ethnicity.
†
Missing values include 0.5% for previous mammography, 14.0% for family history, 11.3% for menopausal status, 30.4% for BI-RADS breast
density, 4.0% for time since previous mammography, and 1.7% for race or ethnicity.
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Table 2
Performance Measures of Screening Mammography Among Women Undergoing 231 034 Digital Versus 638
252 Film-Screen Examinations*
Performance Measure† Digital Mammography Film-Screen Mammography Odds Ratio P Value
Cases of cancer per 1000 examinations
    Total‡ 4.5 (4.0–5.0) 4.6 (4.2–5.0) 1.0 (0.9–1.1) 0.62
    Invasive cancer 3.3 (3.0–3.8) 3.4 (3.1–3.8) 1.0 (0.9–1.1) 0.58
    DCIS 1.1 (0.9–1.3) 1.1 (1.0–1.3) 1.0 (0.8–1.2) 0.81
Cancer detection per 1000 examinations§ 3.8 (3.4–4.2) 3.8 (3.4–4.1.0) 1.0 (0.9–1.1) 0.98
False-negative results per 1000 examinations∥ 0.7 (0.6–0.9) 0.8 (0.7–1.0) 0.9 (0.7–1.1) 0.165
Biopsies per 1000 examinations 11.0 (7.3–16.6) 10.6 (7.0–15.9) 1.0 (1.0–1.1) 0.37
Sensitivity, %¶ 84 (80.8–86.8) 81.9 (79.4–84.2) 1.2 (0.9–1.5) 0.21
Specificity, % 90.4 (88.7–91.9) 91.0 (89.4–92.4) 0.9 (0.9–1.0) <0.001
Positive likelihood ratio** 8.8 (7.3–10.2) 9.1 (7.6–10.6)
Negative likelihood ratio** 0.18 (0.15–0.21) 0.20 (0.17–0.23)
Recall rate, % 10 (8.5–11.7) 9.3 (7.9–11.0) 1.1 (1.1–1.1) <0.001
Positive predictive value, % 3.8 (3.2–4.5) 4.0 (3.4–4.6) 1.0 (0.9–1.1) 0.43
Cancer yield per biopsy, % 25.3 (20.4–31.0) 24.7 (20.5–29.4) 1.0 (0.8–1.3) 0.73
DCIS = ductal carcinoma in situ.
*
Values in parentheses are 95% CIs.
†
Adjusted for site, age, year, and time between screening examinations. Estimates are based on median facility performance.
‡
Invasive cancer or DCIS within 12 mo of a positive screening examination (Breast Imaging Reporting and Data System [BI-RADS] assessment of
needs additional imaging, suspicious, or malignant) or negative screening examination (BI-RADS assessment of negative or benign finding).
§
Invasive cancer or DCIS within 12 mo of a positive screening examination.
∥
Invasive cancer or DCIS within 12 mo of a negative screening examination.
¶
Sensitivity to detect invasive cancer or DCIS within 12 mo of a screening examination.
**
Ratio of women with disease to women without disease for a given test result.
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Table 5








  Patients, n 1026 2915
  Stage, %
    0 25.6 (22.8–28.6) 24.7 (22.9–26.6) 0.078
    I 42.5 (39.2–45.8) 44.6 (42.4–46.8)
    IIA 20.1 (17.5–23.1) 16.8 (15.2–18.5)
    IIB 6.1 (4.6–8.1) 5.6 (4.7–6.8)
    III 5.1 (3.9–6.6) 7.3 (6.1–8.7)
    IV 0.7 (0.3–1.6) 1.1 (0.7–1.6)
Tumor size
  Patients, n 750 2120
  Tumor size, %‡
    <10 mm 38.4 (34.6–42.4) 37.5 (35.0–40.1) 0.82
    11–15 mm 23.9 (20.8–27.4) 23.9 (21.8–26.2)
    16–20 mm 13.1 (10.7–15.9) 14.3 (12.6–16.2)
    >20 mm 24.7 (21.4–28.3) 24.3 (22.2–26.7)
Nodal status
  Patients, n 762 2157
  Nodal status, %‡
    Positive 30.7 (27.1–34.5) 28.8 (26.5–31.2) 0.39
    Negative 69.3 (65.5–72.9) 71.2 (68.8–73.5)
Tumor grade
  Patients, n 727 1983
  Tumor grade, %‡
    I 22.4 (19.2–25.9) 21.8 (19.8–24.0) 0.38
    II 42.8 (39.0–46.8) 46.1 (43.5–48.8)
    III or IV 34.9 (31.1–38.8) 32.2 (29.7–34.8)
Estrogen receptor status
  Patients, n 726 2002
  Status, %‡
    Positive 80.9 (77.4–83.9) 81.7 (79.4–83.7) 0.69
    Negative 19.1 (16.1–22.6) 18.3 (16.3–20.6)
*
Values in parentheses are 95% CIs.
†
Based on likelihood ratio test for difference between film and digital in any level of the cancer characteristic vs. no difference after adjustment for
age, screening interval, examination year, and registry.
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‡
Percentages are based on all women with invasive cancer within 12 mo of screening examination.
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Appendix Table 1
Performance Measures of Screening Mammography Among Women Undergoing 223 900 Digital Versus 611
098 Film-Screen Examinations, Allowing for Facility and Radiologist Random Effects*
Performance Measure† Digital Mammography Film-Screen Mammography Odds Ratio P Value
Cases of cancer per 1000 examinations
    Total‡ 4.4 (4.0–4.9) 4.6 (4.2–5.0) 1.0 (0.9–1.1) 0.62
    Invasive cancer 3.3 (3.0–3.8) 3.4 (3.1–3.8) 1.0 (0.9–1.1) 0.60
    DCIS 1.1 (0.9–1.3) 1.1 (1–1.3) 1.0 (0.8–1.2) 0.77
Cancer detection per 1000 examinations§ 3.7 (3.3–4.2) 3.7 (3.4–4.1) 1.0 (0.9–1.1) 0.93
False-negative results per 1000 examinations∥ 0.7 (0.6–0.9) 0.8 (0.7–1) 0.9 (0.7–1.1) 0.169
Biopsies per 1000 examinations 10.6 (7.2–15.5) 10.4 (7.1–15.1) 1.0 (0.9–1.1) 0.64
Sensitivity, %¶ 84.3 (81–87.1) 82.2 (79.7–84.5) 1.2 (0.9–1.5) 0.22
Specificity, % 91.7 (90.5–92.8) 91.9 (90.7–93) 1.0 (0.9–1.0) 0.012
Recall rate, % 8.7 (7.6–9.9) 8.5 (7.4–9.7) 1.0 (1.0–1.1) 0.013
Positive predictive value, % 3.8 (3.3–4.5) 4.0 (3.5–4.6) 1.0 (0.9–1.1) 0.40
Cancer yield per biopsy, % 25.4 (20.4–31) 24.6 (20.5–29.3) 1.0 (0.8–1.3) 0.71
DCIS = ductal carcinoma in situ.
*
Values in parentheses are 95% CIs.
†
Adjusted for site, age, year, and time between screening examinations. Estimates are based on median facility and radiologist performance.
‡
Invasive cancer or DCIS within 12 mo of a positive screening examination (Breast Imaging Reporting and Data System [BI-RADS] assessment of
needs additional imaging, suspicious, or malignant) or negative screening examination (BI-RADS assessment of negative or benign finding).
§
Invasive cancer or DCIS within 12 mo of a positive screening examination.
∥
Invasive cancer or DCIS within 12 mo of a negative screening examination.
¶
Sensitivity to detect invasive cancer or DCIS within 12 mo of a screening examination.
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Appendix Table 4
Performance Measures of Screening Mammography Among Women Undergoing 231 034 Digital Versus 638





Odds Ratio P Value
Cases of cancer per 1000 examinations
    Total‡ 4.5 (4.0–5.0) 4.5 (4.2–4.7) 1.0 (0.9–1.1) 0.94
    Invasive cancer 3.4 (3.0–3.9) 3.4 (3.2–3.6) 1.0 (0.9–1.1) 0.97
    DCIS 1.1 (0.9–1.3) 1.0 (1–1.1) 1.0 (0.8–1.2) 0.84
Cancer detection per 1000 examinations§ 3.8 (3.4–4.3) 3.7 (3.5–4) 1.0 (0.9–1.1) 0.58
False-negative results per 1000 examinations∥ 0.7 (0.5–0.9) 0.7 (0.7–0.8) 0.9 (0.7–1.1) 0.30
Biopsies per 1000 examinations 11.0 (8.4–14.4) 10.6 (8.2–13.6) 1.0 (0.9–1.1) 0.40
Sensitivity, %¶ 85.6 (81.6–88.8) 83.4 (82.0–84.8) 1.2 (0.9–1.6) 0.23
Specificity, % 91.3 (90.3–92.2) 91.9 (91.0–92.7) 0.9 (0.9–1.0) <0.001
Recall rate, % 9.1 (8.2–10.0) 8.5 (7.7–9.4) 1.1 (1.1–1.1) <0.001
Positive predictive value, % 4.1 (3.6–4.8) 4.3 (3.9–4.7) 1.0 (0.9–1.1) 0.59
Cancer yield per biopsy, % 26.5 (21.7–31.8) 25.1 (22.5–27.9) 1.1 (0.9–1.3) 0.52
DCIS = ductal carcinoma in situ.
*
Values in parentheses are 95% CIs.
†
Adjusted for site, age, year, and time between screening examinations. Estimates are based on within-facility effects, holding between-facility
effects constant and evaluated at median facility performance.
‡
Invasive cancer or DCIS within 12 mo of a positive screening examination (Breast Imaging Reporting and Data System [BI-RADS] assessment of
needs additional imaging, suspicious, or malignant) or negative screening examination (BI-RADS assessment of negative or benign finding).
§
Invasive cancer or DCIS within 12 mo of a positive screening examination.
∥
Invasive cancer or DCIS within 12 mo of a negative screening examination.
¶
Sensitivity to detect invasive cancer or DCIS within 12 mo of a screening examination.
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